{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-054294","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2026-08-06T20:08:36+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:11:47.699713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income","bullets":["Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.","Non-GAAP net income $6.3M ($0.13/share) vs $10.7M ($0.24/share) in Q2 2025; adjusted EBITDA $26.4M, up 7% YoY.","On-X revenue grew 18% constant currency; stent grafts grew 12% constant currency; AMDS and NEXUS highlighted.","Received U.S. FDA PMA approval for AMDS Hybrid Prosthesis; completed acquisition of Endospan Ltd. in May 2026.","Reiterated FY2026 revenue guidance $480-496M (7-11% constant currency growth) and adjusted EBITDA $92-99M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-054294","json":"https://secwatch.observer/filing/0001628280-26-054294.json","markdown":"https://secwatch.observer/filing/0001628280-26-054294.md","text":"https://secwatch.observer/filing/0001628280-26-054294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/0001628280-26-054294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/aort-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:11:47.699713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}